Summit Therapeutics to unveil ten ivonescimab studies, including Phase III survival win, at ESMO 2026
Summit Therapeutics (SMMT) and partner Akeso Inc. will present ten ivonescimab studies at the European Society for Medical Oncology meeting in Madrid. The highlight is the Phase III HARMONi‑GI1 trial that showed a statistically significant overall‑survival benefit for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first‑line advanced biliary tract cancer. Over 5,000 patients have already received ivonescimab in clinical studies worldwide, and a U.S. Phase II/III trial (EA2251) has just started.
Why it matters
The positive overall‑survival data could increase investor expectations for future regulatory approvals and commercial launch of ivonescimab, potentially boosting Summit’s valuation. The breadth of data across multiple tumor types signals a broad development program that may create additional revenue opportunities.
Key facts
- 1Summit Therapeutics will present ten ivonescimab studies at ESMO 2026. stocktitan.net
- 2The Phase III HARMONi‑GI1 trial showed positive overall‑survival results for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first‑line advanced biliary tract cancer. stocktitan.net
- 3More than 5,000 patients have been treated with ivonescimab in clinical studies globally. stocktitan.net
- 4Seventeen Phase III clinical studies of ivonescimab are announced, ongoing, or completed. stocktitan.net
- 5A U.S. Phase II/III trial, EA2251, has begun. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.